A
Anna I. Rychlewska-Hanczewksa
Publications - 1
Citations - 294
Anna I. Rychlewska-Hanczewksa is an academic researcher. The author has contributed to research in topics: Placebo & Psoriatic arthritis. The author has an hindex of 1, co-authored 1 publications receiving 235 citations.
Papers
More filters
Journal ArticleDOI
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash,Bruce Kirkham,Masato Okada,Proton Rahman,B. Combe,Gerd Burmester,David H. Adams,Lisa Kerr,Chin Lee,Catherine L Shuler,Mark C. Genovese,Khalid Ahmed,Jeffrey Alper,Nichol Barkham,Ralph E. Bennett,Francisco Javier Blanco Garcia,Ricardo Blanco Alonso,Howard B. Blumstein,Michael S. Brooks,Gerd R Burmester,Patricia Cagnoli,Paul H. Caldron,Alain Cantagrel,Der Yuan Chen,Melvin Churchill,Christine E Codding,Peter M.G. Deane,Jose Del Giudice,Atul Deodhar,Rajat K. Dhar,Eva Dokoupilova,Rita M. Egan,Andrea Everding,Eva Galíndez,David H. Goddard,Alice B. Gottlieb,Philippe Goupille,Robert M. Griffin,Ramesh C. Gupta,Stephen B. Hall,Kalpita Hatti,Mary P. Howell,Yu-Huei Huang,Ramina Jajoo,Namieta M. Janssen,Uta Kiltz,Alan Kivitz,Steven J. Klein,Mariusz P. Korkosz,Roshan Kotha,Joel M. Kremer,Cummins Lue,José Luis Marenco de la Fuente,Helena Marzo-Ortega,Jordi Gratacós Masmitjà,Philip J. Mease,Pier Luigi Meroni,Eric C. Mueller,Anupama C. Nandagudi,Antonio Fernández-Nebro,Clark M. Neuwelt,Ana Maria Orbai,Meera R. Oza,Deborah L. Parks,Debendra Pattanaik,Maria Rell-Bakalarska,David H. Rosmarin,Euthalia Roussou,Anna I. Rychlewska-Hanczewksa,David H. Sikes,Michael T. Stack,Prashanth Sunkureddi,Hasan Tahir,Diamant Thaçi,Tsen-Fang Tsai,Anthony M. Turkiewicz,Leonore Unger,Raúl Veiga Cabello,Ulf Wagner,Cheng Chung Wei,Alvin F. Wells,Peter Youssef,Agnieszka Zielinska +82 more
TL;DR: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixeksedumab.